Catalent, Inc. to Present at the 39th Annual J.P. Morgan Healthcare Conference
Catalent, Inc. (NYSE: CTLT) announced that its executive leadership team will present virtually at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the 39th Annual J.P. Morgan Healthcare Conference at 8:20 a.m. ET on January 11, 2021.
A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs more than 14,000 people, including approximately 2,500 scientists, at more than 40 facilities across four continents and in fiscal 2020 generated over
More products. Better treatments. Reliably supplied.™
View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005238/en/